Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 04, 2015 10:46 AM ET


Company Overview of Banner Pharmacaps Inc.

Company Overview

Banner Pharmacaps Inc. operates as a gelatin-based drug delivery and specialty pharmaceutical company in the United States. It specializes in the research, development, manufacture, and distribution of soft-gelatin pharmaceutical, over-the-counter, and nutritional consumer products. The company offers gelatin capsules, enteric softgels, solubility enhancing products, gelcaps, chewable liquid-filled softgels, chewable gels, controlled release softgels, and non-animal softgels. It serves consumer healthcare and prescription markets, including pharmaceutical, biotech, and nutritional companies worldwide. The company was incorporated in 1992 and is headquartered in High Point, North Carolina. It...

4100 Mendenhall Oaks Parkway

Suite 301

High Point, NC 27265

United States

Founded in 1992





Key Executives for Banner Pharmacaps Inc.

Banner Pharmacaps Inc. does not have any Key Executives recorded.

Banner Pharmacaps Inc. Key Developments

Mylan Pharmaceuticals Inc. and Banner Pharmacaps Inc. Enter into Settlement and License Agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l

Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic version of TARGRETIN(R), which is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Pursuant to the agreement, the pending litigation will be dismissed, and Mylan and Banner will receive a license to begin selling a generic version of the product on July 9, 2015, or earlier under certain circumstances. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. Mylan believes that its partner, Banner, is the first company to have filed a substantially complete abbreviated new drug application (ANDA) containing a Paragraph IV certification with the U.S. Food and Drug Administration (FDA) for Bexarotene Capsules, 75 mg. TARGRETIN(R), 75 mg, had U.S. sales of approximately $53.6 million for the 12 months ending Sept. 30, 2013. Currently, Mylan has 178 ANDAs pending FDA approval representing $90.8 billion in annual sales, according to IMS Health. Thirty-nine of these pending ANDAs are potential first-to-file opportunities, representing $23.8 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health. When including ANDAs associated with Mylan's recent acquisition of Agila, the company now has a total of 300 ANDAs pending FDA approval.

Depomed, Inc. Files a Patent Infringement Lawsuit against Banner Pharmacaps Inc. and Watson Laboratories, Inc

Depomed, Inc. announced it has filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Banner Pharmacaps Inc. and Watson Laboratories, Inc. Banner Pharmacaps has filed an Abbreviated New Drug Application (ANDA) with the FDA to market generic Zipsor(R) (diclofenac potassium) 25mg capsules and has granted to Watson Laboratories exclusive rights to the proposed generic product. The lawsuit claims infringement of Depomed's five US patents listed for Zipsor in the FDA's Orange Book, the last of which expires in 2029, by the defendants' proposed generic product. Depomed has received a Paragraph IV certification notice from Banner Pharmacaps alleging that Depomed's patents will not be infringed by the proposed generic product, or the patents are invalid or unenforceable. Depomed commenced the lawsuit within the 45 days required to automatically stay, or bar, the FDA from approving the Zipsor ANDA for 30 months from the date of receipt by Depomed of the notice (December 2015) or until a district court decision that is adverse to the patents, whichever may occur earlier.

Similar Private Companies By Industry

Company Name Region
Murty Pharmaceuticals Incorporated United States
VersaPharm Incorporated United States
Cortice Biosciences Incorporated United States
Humanetics Corporation United States
TargeGen, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Banner Pharmacaps Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at